Efficacy of anakinra as a treatment for recurrent pericarditis

Loza, Sara Murias; Silva, Luis García-Guereta; Rueda, Rosa María Alcobendas; Camba, Agustín Remesal

doi:10.1016/j.anpede.2017.05.005

Cited by 1 publication

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several observational studies summarized data on the efficacy of anakinra in pediatric ( Picco et al, 2009 ; Scardapane et al, 2013 ; Finetti et al, 2014 ; Murias Loza et al, 2018 ) and adult IRP patients ( Vassilopoulos et al, 2012 ; Lazaros et al, 2014 ). The results of a single randomized AIRTRIP study by Brucato et al (2016) involving 34 patients with IRP were impressive.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Interleukin-1 Blockade in Polygenic Autoinflammatory Disorders: Where Are We now?

et al. 2021

View full text Add to dashboard Cite

Polygenic autoinflammatory diseases (AIDs), such as systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease, Kawasaki disease, idiopathic recurrent pericarditis (IRP), Behçet’s Syndrome, Crystal-induced arthropatihes such as gout or Calcium pyrophosphate deposition disease are characterized by the overexpression of inflammasome-associated genes, leading to a dysregulation of the innate immune response. The IL-1 cytokine family (IL-1α, IL-1β, IL-1Ra, IL-18, IL-36Ra, IL-36α, IL-37, IL-36β, IL-36g, IL-38, IL-33) was defined to be principally responsible for the inflammatory nature of polygenic AIDs. Several clinical trials were initiated, and IL-1 blockade has been proven to cause a rapid reduction of clinical symptoms and normalization of laboratory parameters in the majority of cases. Randomized, placebo-controlled, clinical trials, together with registry-based clinical trials and open-label, retrospective and prospective observational studies, supported the efficacy and safety of IL-1 inhibitors in the treatment of polygenic AIDs. Most of the current data are focused on the therapeutic use of anakinra, an IL-1 receptor antagonist, canakinumab, an anti-IL-1β monoclonal antibody, and rilonacept, a soluble decoy receptor. However, other promising agents, such as gevokizumab, IL-1β blocking monoclonal antibody, tadekinig alfa, a human recombinant IL-18-binding protein, and tranilast, an analog of a tryptophan metabolite, are currently being tested. Anakinra, canakinumab and rilonacept caused impressive improvements in both systemic and musculoskeletal symptoms. Furthermore, the anti-IL-1 therapy allowed corticosteroid tapering and, in some cases, even withdrawal. This article reviews the current IL-1 inhibitors and the results of all clinical trials in which they have been tested for the management of broad spectrum of polygenic AIDs.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The flare-free intervals were also prolonged from the mean 157 days to 10 months ( Imazio et al, 2020 ). However, preventing pericarditis recurrence after anakinra withdrawal remains a challenge ( Picco et al, 2009 ; Scardapane et al, 2013 ; Finetti et al, 2014 ; Brucato et al, 2016 ; Murias Loza et al, 2018 ).…”

Section: Methodsmentioning

confidence: 99%